Ardelyx (ARDX) Competitors

Ardelyx (NASDAQ:ARDX) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.

Is ARDX or AKRO more profitable?

Akero Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -11.73%. Ardelyx's return on equity of -24.87% beat Akero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-11.73%	-24.87%	-10.51%
Akero Therapeutics	N/A	-32.46%	-29.83%

Do insiders & institutionals believe in ARDX or AKRO?

58.9% of Ardelyx shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by company insiders. Comparatively, 7.9% of Akero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, ARDX or AKRO?

Ardelyx has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500.

Do analysts prefer ARDX or AKRO?

Ardelyx presently has a consensus price target of $10.39, indicating a potential upside of 160.37%. Akero Therapeutics has a consensus price target of $82.33, indicating a potential upside of 70.29%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Akero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90
Akero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation & earnings, ARDX or AKRO?

Ardelyx has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$361.71M	2.64	-$39.14M	-$0.22	-18.14
Akero Therapeutics	N/A	N/A	-$151.76M	-$1.95	-24.79

Does the media prefer ARDX or AKRO?

In the previous week, Akero Therapeutics had 1 more articles in the media than Ardelyx. MarketBeat recorded 13 mentions for Akero Therapeutics and 12 mentions for Ardelyx. Akero Therapeutics' average media sentiment score of 0.88 beat Ardelyx's score of 0.85 indicating that Akero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Akero Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer ARDX or AKRO?

Ardelyx received 421 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 67.46% of users gave Ardelyx an outperform vote while only 65.56% of users gave Akero Therapeutics an outperform vote.

Company	Underperform	Outperform
Ardelyx	Outperform Votes 539 67.46%	Underperform Votes 260 32.54%
Akero Therapeutics	Outperform Votes 118 65.56%	Underperform Votes 62 34.44%

Summary

Ardelyx beats Akero Therapeutics on 11 of the 18 factors compared between the two stocks.